Informed consent for prostate-specific antigen screening

Urology

Volumn 61, Issue 1, 2003, Pages 2-4

  Wilkinson, Simon ^a,b   Chodak, Gerald ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b WEISS MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BREAST CARCINOMA; CANADA; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; EDITORIAL; FOLLOW UP; GERMANY; HISTOPATHOLOGY; HUMAN; INFORMED CONSENT; MALE; MAMMOGRAPHY; NEUROBLASTOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SCREENING TEST; UNITED STATES; URINALYSIS;

HEALTH CARE AND PUBLIC HEALTH; PROFESSIONAL PATIENT RELATIONSHIP;

CONSENT FORMS; HUMANS; INFORMED CONSENT; MALE; MASS SCREENING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 0037256494     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02010-1     Document Type: Editorial

References (18)

1. Jemal A., Thomas A., Murray T., et al. Cancer statistics, 2002. CA Cancer J Clin. 52:2002;23-47.
2. Smith RA, von Eschenbach AC, Wender R, et al: American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001 - testing for early lung cancer detection. CA Cancer J Clin 51: 38-75; quiz 77-80, 2001.
3. Minnesota Department of Health: Cancer data from the Minnesota Cancer Surveillance System. Available at: http://www.cancer.umn.edu. Accessed June 20, 2002.
4. Greenlee R.T., Hill-Harmon M.B., Thun M. Cancer statistics. CA Cancer J Clin. 51:2001;15-36.
5. Albertsen P.C., Fryback D.G., Storer B.E., et al. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 274:1995;626-631.
6. Oliver S.E., Gunnell D., Donovan J.L. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet. 355:2000;1788-1789.
7. Gotzsche P.C., Olsen O. Is screening for breast cancer with mammography justifiable? Lancet. 355:2000;129-134.
8. Black W.C., Haggstrom D.A., Welch H.G. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst. 94:2002;167-173.
9. Schilling F.H., Spix C., Berthold F., et al. Neuroblastoma screening at one year of age. N Engl J Med. 346:2002;1047-1053.
10. Woods W.G., Gao R.N., Shuster J.J., et al. Screening infants and mortality due to neuroblastoma. N Engl J Med. 346:2002;1041-1046.
11. Yoneda A., Oue T., Imura K., et al. Observation of untreated patients with neuroblastoma detected by mass screening a "wait and see" pilot study. Med Pediatr Oncol. 36:2001;160-162.
12. Roter D.L., Hall J.A., Merisca R., et al. Effectiveness of interventions to improve patient compliance a meta-analysis. Med Care. 36:1998;1138-1161.
13. Morris J., Royle G.T. Choice of surgery for early breast cancer pre- and postoperative levels of clinical anxiety and depression in patients and their husbands. Br J Surg. 74:1987;1017-1019.
14. Bertakis K.D. The communication of information from physician to patient a method for increasing patient retention and satisfaction. J Fam Pract. 5:1977;217-222.
15. Kaplan S.H., Greenfield S., Ware J.E. Jr. Assessing the effects of physician-patient interactions on the outcomes of chronic disease. Med Care. 27:1989;S110-S127.
16. Greenfield S., Kaplan S.H., Ware J.E. Jr, et al. Patients' participation in medical care effects on blood sugar control and quality of life in diabetes. J Gen Intern Med. 3:1988;448-457.
17. Schroder F.H., Wildhagen M.F. Screening for prostate cancer evidence and perspectives. BJU Int. 88:2001;811-817.
18. Cockburn J., Redman S., Mill D., et al. Public understanding of medical screening. J Med Screen. 2:1995;224-227.